CCM SRX
Alternative Names: CCM-SRXLatest Information Update: 06 Oct 2023
At a glance
- Originator CCM Biosciences
- Class Antidementias; Antiparkinsonians; Infertility therapies; Small molecules
- Mechanism of Action SIRT3 protein activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Infertility; Parkinson's disease
Most Recent Events
- 27 Sep 2023 CCM Biosciences has patent protection for Sirtuin activators in undisclosed location (CCM Biosciences website, September 2023)
- 27 Sep 2023 CCM Biosciences has patent protection for small molecule discovery platform in USA (CCM Biosciences website, September 2023)
- 27 Sep 2023 CCM Biosciences has patents pending for small molecule discovery platform in US (CCM Biosciences website, September 2023)